Boston Trust Walden’s Clorox CLX Stock Holding History

Boston Trust Walden’s Portfolio CLX Stock Details CLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,048	Closed	-$376K	–	388
2025 Q3	$376K	Sell	3,048 -304,102	-99%	-$37.7M	﹤0.01%	352
2025 Q2	$36.9M	Buy	307,150 +21,915	+8%	+$2.92M	0.26%	144
2025 Q1	$42M	Buy	285,235 +414	+0.1%	+$63.2K	0.31%	129
2024 Q4	$46.3M	Buy	284,821 +10,913	+4%	+$1.79M	0.32%	123
2024 Q3	$44.6M	Buy	273,908 +268,966	+5,442%	+$39.9M	0.31%	129
2024 Q2	$674K	Sell	4,942 -765	-13%	-$106K	0.01%	300
2024 Q1	$874K	Sell	5,707 -3,480	-38%	-$519K	0.01%	283
2023 Q4	$1.31M	Sell	9,187 -1,305	-12%	-$174K	0.01%	264
2023 Q3	$1.38M	Sell	10,492 -1,320	-11%	-$201K	0.01%	261
2023 Q2	$1.88M	Hold	11,812	–	–	0.02%	249
2023 Q1	$1.87M	Sell	11,812 -2,259	-16%	-$339K	0.02%	250
2022 Q4	$1.97M	Sell	14,071 -1,250	-8%	-$177K	0.02%	252
2022 Q3	$1.97M	Sell	15,321 -1,420	-8%	-$205K	0.02%	251
2022 Q2	$2.36M	Sell	16,741 -3,368	-17%	-$481K	0.02%	250
2022 Q1	$2.8M	Sell	20,109 -19,466	-49%	-$2.98M	0.02%	248
2021 Q4	$6.9M	Buy	39,575 +6,355	+19%	+$1.06M	0.06%	229
2021 Q3	$5.5M	Buy	33,220 +170	+0.5%	+$29.3K	0.05%	231
2021 Q2	$5.95M	Buy	33,050 +5,865	+22%	+$1.07M	0.05%	232
2021 Q1	$5.24M	Sell	27,185 -9,295	-25%	-$1.79M	0.05%	230
2020 Q4	$7.37M	Sell	36,480 -4,381	-11%	-$907K	0.08%	217
2020 Q3	$8.59M	Sell	40,861 -4,468	-10%	-$995K	0.11%	203
2020 Q2	$9.94M	Sell	45,329 -97,890	-68%	-$19.6M	0.13%	195
2020 Q1	$24.8M	Sell	143,219 -90,814	-39%	-$15M	0.4%	72
2019 Q4	$35.9M	Buy	234,033 +12,293	+6%	+$1.84M	0.42%	74
2019 Q3	$33.7M	Sell	221,740 -1,755	-0.8%	-$277K	0.42%	71
2019 Q2	$34.2M	Buy	223,495 +3,595	+2%	+$549K	0.45%	68
2019 Q1	$35.3M	Sell	219,900 -7,720	-3%	-$1.2M	0.48%	62
2018 Q4	$35.1M	Buy	227,620 +705	+0.3%	+$110K	0.56%	51
2018 Q3	$34.1M	Buy	226,915 +9,355	+4%	+$1.33M	0.47%	62
2018 Q2	$29.4M	Buy	217,560 +200,856	+1,202%	+$24.8M	0.43%	72
2018 Q1	$2.22M	Buy	16,704 +829	+5%	+$111K	0.03%	268
2017 Q4	$2.36M	Sell	15,875 -175	-1%	-$23.8K	0.03%	269
2017 Q3	$2.12M	Buy	16,050 +750	+5%	+$101K	0.03%	276
2017 Q2	$2.04M	Sell	15,300 -50	-0.3%	-$6.75K	0.03%	271
2017 Q1	$2.07M	Sell	15,350 -250	-2%	-$32.4K	0.03%	264
2016 Q4	$1.87M	Buy	15,600 +150	+1%	+$17.7K	0.03%	268
2016 Q3	$1.93M	Buy	15,450 +215	+1%	+$28.2K	0.03%	267
2016 Q2	$2.11M	Sell	15,235 -875	-5%	-$113K	0.04%	264
2016 Q1	$2.03M	Sell	16,110 -1,075	-6%	-$137K	0.04%	267
2015 Q4	$2.18M	Buy	17,185 +1,060	+7%	+$132K	0.04%	257
2015 Q3	$1.86M	Sell	16,125 -1,375	-8%	-$154K	0.03%	263
2015 Q2	$1.82M	Buy	17,500 +150	+0.9%	+$16.2K	0.03%	261
2015 Q1	$1.92M	Hold	17,350	–	–	0.03%	249
2014 Q4	$1.81M	Hold	17,350	–	–	0.03%	251
2014 Q3	$1.67M	Sell	17,350 -100	-0.6%	-$9.04K	0.03%	251
2014 Q2	$1.59M	Sell	17,450 -100	-0.6%	-$8.96K	0.02%	248
2014 Q1	$1.54M	Buy	17,550 +5,025	+40%	+$441K	0.02%	239
2013 Q4	$1.16M	Buy	12,525 +75	+0.6%	+$6.76K	0.02%	253
2013 Q3	$1.02M	Buy	12,450 +150	+1%	+$12.7K	0.02%	254
2013 Q2	$1.02M	Buy	+12,300	New	+$1.06M	0.02%	242

Other funds holding CLX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Boston Trust Walden's CLX Position: Q4 2025 in Review

Boston Trust Walden sold out of Clorox (CLX) in Q4 2025, closing a stake of 3,048 shares — an estimated $376K sold.

Boston Trust Walden first reported a position in CLX in Q2 2013 and held it in 50 quarters. The position peaked at $46.3M in Q4 2024. 1,050 funds tracked by Wall St. Rank hold CLX as of Q4 2025.

Boston Trust Walden reported no remaining Clorox position as of Q4 2025 after selling out during the quarter.
Boston Trust Walden sold 3,048 Clorox shares in Q4 2025, an estimated $376K.
Boston Trust Walden first reported a position in Clorox in Q2 2013 and held it in 50 quarters.
Boston Trust Walden's Clorox position peaked at $46.3M in Q4 2024.
1,050 funds tracked by Wall St. Rank held Clorox as of Q4 2025.

Based on Boston Trust Walden's 13F filing for Q4 2025, filed 28 Jan 2026.